Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Astrazeneca (AZN)

Price 12,180.00p on 26-07-2024 at 16:30:01
Change 120.00p 1%
Buy 12,198.00p
Sell 12,196.00p
Buy / Sell AZN Shares
Last Trade: Sell 19.00 at 12,180.00p
Day's Volume: 1,499,036
Last Close: 12,180.00p
Open: 12,116.00p
ISIN: GB0009895292
Day's Range 12,114.00p - 12,332.00p
52wk Range: 9,461.00p - 12,704.00p
Market Capitalisation: £188,823m
VWAP: 12,192.85876p
Shares in Issue: 1,550m

Recent Trades History Astrazeneca (AZN)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 19 12,180.00p SI Trade
Suspected SELL Trade
15:49:11 - 26-Jul-24
Unknown* 774 12,180.00p OTC Trade
15:35:24 - 26-Jul-24
Unknown* 296 12,180.00p OTC Trade
15:35:24 - 26-Jul-24
Unknown* 53 12,180.00p OTC Trade
15:35:24 - 26-Jul-24
Unknown* 138 12,180.00p OTC Trade
15:35:24 - 26-Jul-24
Buy* 759,678 12,180.00p Suspected BUY Trade
15:35:24 - 26-Jul-24
Unknown* 0 12,180.00p OTC Trade
15:20:30 - 26-Jul-24
Unknown* 0 12,186.00p OTC Trade
15:07:12 - 26-Jul-24
Unknown* 0 12,190.00p OTC Trade
15:04:14 - 26-Jul-24
Unknown* 0 12,190.00p OTC Trade
15:04:14 - 26-Jul-24

Share Price History for Astrazeneca

Time period:
to
Date Open High Low Close Volume

Share News for Astrazeneca

EXECUTIVE CHANGES: Morgan Advanced Materials picks senior director

26th Jul 2024 15:27

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Wednesday and Thursday and not separately reported by Alliance News: Read More

IN BRIEF: Astra pushes to get Imfinzi approved for lung cancer in US

26th Jul 2024 13:27

AstraZeneca PLC - Cambridge, England-based pharmaceutical firm - Says it is "committed to working closely" with the US Food & Drug Administration to bring an Imfinzi-based treatment to patients with resectable non-small cell lung cancer, following a review of a phase III trial by the Oncologic Drugs Advisory Committee, an advisory body for the FDA. Astra says the Aegean trial of Imfinzi, whose generic name is durvalumab, showed a "statistically significant and clinically meaningful 32% reduction in the risk of recurrence, progression events or death versus chemotherapy alone". Read More

LONDON BROKER RATINGS: Greencore and Hammerson cut to 'hold'

26th Jul 2024 09:43

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and on Thursday: Read More

LONDON MARKET MIDDAY: Drab earnings unnerve equities before US data

25th Jul 2024 12:10

(Alliance News) - European equities tumbled on Thursday, with tepid earnings causing a sea of red across major benchmarks, compounding already fragile sentiment after a sell-off in New York. Read More

TOP NEWS: AstraZeneca shares fall despite improved full-year outlook

25th Jul 2024 09:37

(Alliance News) - AstraZeneca PLC on Thursday raised its annual guidance as it hailed "strong growth in the first half of the year". Read More

FTSE 100 Latest
Value8,285.71
Change99.36

Login to your account

Forgot Password?

Not Registered